Skip to main content
. 2023 Oct 26;14:1249462. doi: 10.3389/fimmu.2023.1249462

Figure 1.

Figure 1

Study design and outcomes. SARS-CoV-2 infection and COVID-19 severity were evaluated in the AZD7442 group (33 patients), the no-AZD7442 group (170 patients) and in patients with a recent SARS-CoV-2 infection (35 patients). COVID-19, coronavirus-19 disease; IEI, inborn errors of immunity; IgRT, immunoglobulin replacement therapy; IgG, immunoglobulin G; n, number; PrEP, pre-exposure prophylaxis; SARS-CoV2, Severe acute respiratory syndrome coronavirus 2.